{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:58:43Z","timestamp":1790135923205,"version":"4.0.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background and Purpose<\/jats:title><jats:p>Two clinical trials assessing the steroid-sparing effect of methotrexate (MTX) yielded conflicting results. Our objective was to investigate whether MTX would show a steroid-sparing effect in the treatment of generalized myasthenia gravis (MG) patients who fitted Myasthenia Gravis Foundation of America (MGFA) Class II and Class III.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed an 18-month prospective, randomized, open-labeled trial of prednisone combined with MTX 10 mg orally every week versus prednisone alone in 40 recently diagnosed MG patients of MGFA Class II and Class III between July 2014 and July 2018. The primary endpoint was the prednisone area under the dose\u2013time curve (AUDTC) from months 3 to 18. Secondary endpoints included changes of the Quantitative Myasthenia Gravis Score (QMG), the Myasthenia Gravis Activity of Daily Living Score (MG-ADL), initial time of prednisone reduction, the median prednisone daily dose in each month, adverse events, and treatment failures in each group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty participants were included; among those, 5 individuals withdrew. A total of 35 participants completed 18 months of follow-up (18 in prednisone+MTX, 17 in prednisone group). Combined use of MTX reduced the month 3\u201318 prednisone AUDTC (prednisone+MTX 5,663.44 \u00b1 1,678.08 mg, prednisone 6,683.94 \u00b1 678.08 mg, <jats:italic>p<\/jats:italic> = 0.03, 95% confidence interval -1916.01 to -124.98). The initial times of prednisone reduction were 4.34 \u00b1 1.44 months in the prednisone+MTX group and 5.56 \u00b1 2.05 months in the prednisone group (<jats:italic>p<\/jats:italic> = 0.04, 95% CI -2.41 to -0.03). The median daily prednisone dose was significantly lower in the prednisone+MTX group at month 6 and months 9\u201318. No significant differences were found in QMG and MG-ADL scores between the two groups. No serious drug-related adverse events were observed in both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provides evidence that MTX has the steroid-sparing ability in generalized MG patients of MGFA Class II and Class III.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>http:\/\/www.chictr.org.cn\/showproj.aspx?proj=10563<\/jats:uri> identifier ChiCTR-IPR-15006081.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.839075","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T04:49:07Z","timestamp":1647578947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis"],"prefix":"10.3389","volume":"13","author":[{"given":"Li","family":"Di","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faxiu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and Immunosuppressant Drugs in Myasthenia Gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.50.6.1778","article-title":"A Randomized Double-Blind Trial of Prednisolone Alone or With Azathioprine in Myasthenia Gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A Clinical Therapeutic Trial of Cyclosporine in Myasthenia Gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CND.0000000000000133","article-title":"Nicolle MW. A Review of Azathioprine-Associated Hepatotoxicity and Myelosuppression in Myasthenia Gravis","volume":"18","author":"Jack","year":"2016","journal-title":"J Clin Neuromuscul Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An International, Phase III, Randomized Trial of Mycophenolate Mofetil in Myasthenia Gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, Double-Blind, Placebo-Controlled Study of Tacrolimus in Myasthenia Gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the Treatment of Myasthenia Gravis in Patients With an Inadequate Response to Glucocorticoid Therapy: Randomized, Double-Blind, Placebo-Controlled Study Conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and Efficacy of Eculizumab in Anti-Acetylcholine Receptor Antibody-Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340805","article-title":"Methotrexate Versus Azathioprine in the Treatment of Rheumatoid Arthritis. A Forty-Eight-Week Randomized, Double-Blind Trial","volume":"34","author":"Jeurissen","year":"1991","journal-title":"Arthritis Rheum"},{"key":"B11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.410370108","article-title":"Low-Dose (7.5 Mg) Oral Methotrexate Reduces the Rate of Progression in Chronic Progressive Multiple Sclerosis","volume":"37","author":"Goodkin","year":"1995","journal-title":"Ann Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14057","article-title":"Optimising Low-Dose Methotrexate for Rheumatoid Arthritis-A Review","volume":"85","author":"Lucas","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate\u2013How Does it Really Work","volume":"6","author":"Chan","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-005-1355-8","article-title":"Low Dose Methotrexate Induces Apoptosis With Reactive Oxygen Species Involvement in T Lymphocytic Cell Lines to a Greater Extent Than in Monocytic Lines","volume":"54","author":"Herman","year":"2005","journal-title":"Inflamm Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms21103483","article-title":"Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers","volume":"21","author":"Kozminski","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.nmd.2014.02.010","article-title":"The Effects of Prednisone and Steroid-Sparing Agents on Decay Accelerating Factor (CD55) Expression: Implications in Myasthenia Gravis","volume":"24","author":"Auret","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-97","article-title":"A Single-Blinded Trial of Methotrexate Versus Azathioprine as Steroid-Sparing Agents in Generalized Myasthenia Gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A Randomized Controlled Trial of Methotrexate for Patients With Generalized Myasthenia Gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1212\/WNL.0000000000002818","article-title":"Comment: Methotrexate for Patients With Generalized Myasthenia Gravis","volume":"87","author":"Drachman","year":"2016","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0000000000003548","article-title":"Letter Re: A Randomized Controlled Trial of Methotrexate for Patients With Generalized Myasthenia Gravis","volume":"88","author":"Kelkar","year":"2017","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0000000000003547","article-title":"Letter Re: A Randomized Controlled Trial of Methotrexate for Patients With Generalized Myasthenia Gravis","volume":"88","author":"Heckmann","year":"2017","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003549","article-title":"Author Response: A Randomized Controlled Trial of Methotrexate for Patients With Generalized Myasthenia Gravis","volume":"88","author":"Pasnoor","year":"2017","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV Immunoglobulin in Patients With Myasthenia Gravis: A Randomized Controlled Trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of Myasthenia Gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.5407","article-title":"Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial","volume":"78","author":"Sharshar","year":"2021","journal-title":"JAMA Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1007-7480.2010.04.014","article-title":"Chinese Guideline for the Diagnosis and Treatment of Rheumatoid Arthritis","volume":"14","year":"2010","journal-title":"Zhonghua Feng Shi Bing Xue Za Zhi"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06804.x","article-title":"Phase II Trial of Methotrexate in Myasthenia Gravis","volume":"1275","author":"Pasnoor","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e148791","DOI":"10.1371\/journal.pone.0148791","article-title":"Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach","volume":"11","author":"Nair","year":"2016","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23164","article-title":"Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients","volume":"69","author":"Bergstra","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-","article-title":"Efficacy and Safety of Ascending Methotrexate Dose in Combination With Adalimumab: The Randomised CONCERTO Trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.839075\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T04:49:10Z","timestamp":1647578950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.839075\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2022.839075"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.839075","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"article-number":"839075"}}